Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Passage BIO, Inc.

NASDAQ: PASG · Life Sciences · 2 alerts · CIK 1787297

Share price
$4.13Close, Nov 16
Market cap
$13.3M
Shares outstanding
3.22MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Passage BIO, Inc. filings on SEC EDGAR ↗

7:16 AM ET 10-Q
Financial Results

Passage BIO Q3 2026 Results: Net Loss of $4.72M, Loss Narrows

Passage Bio reported a net loss of $20.1 million for the nine months ended September 30, 2026, as it began winding down its gene therapy programs and entered into a merger agreement. Total assets decreased significantly from $62.3 million at year-end 2025 to $20.8 million, primarily due to the reduction in cash and the termination of lease assets.

Key figure
Net loss $4.72M
6:06 AM ET 8-K
Stock Plan Amendment

Passage BIO Stock Plan Amendment

Passage Bio stockholders approved the 2026 Equity Incentive Plan at a special meeting, which will become effective upon the completion of the company's merger with Remix Therapeutics. The plan reserves 5,772,500 shares for issuance and is intended to replace existing equity incentive plans from both companies. The plan also includes an evergreen provision for annual share increases through 2036.

Counterparty
Remix Therapeutics, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.